Bentham Science Neuroscience Collection

 

Neuroscience

THE COLLECTION INCLUDE ARTICLES FROM THESE JOURNALS

 

CN_4-4.jpg CNSAMC.JPG cnsnddt-flyer.jpg carcnr-flyer

and many more Books…

✔ 130 Journals

✔ 7 Book Series

✔ 45 Books in Total 

 

FEATURES AND BENEFITS: 

♦ Access to over 11,130 scholarly articles covering several aspects of Neuroscience

♦ Contents come from more than 100 Bentham Science Journals

♦ Includes both; Original Research and Review Articles

♦ Research from leading institutions in USA, EUROPE, AUSTRALIA, JAPAN, CHINA and other regions

♦ Suitable for researchers in industry and academia wishing to keep updated with latest developments

♦ Easy access to institutions and individuals through IP-based authentication

♦ Access new Neuroscience Research included in this collection as soon as it is published

 

FLEXIBLE PACKAGES 

 Over 2,000 articles from 2017-2018
 Over 3,000 articles from the last 3 years 
 More than 10,000 articles from the last 10 years

 

Annual addition of over 900 Neuroscience related articles each year

Tailor-made packages available for pharmaceuticals companies, research institutes, universities, hospitals, clinical/academic societies, and corporations.

You can also send your librarian’s contact information to us at marketing@benthamscience.net  CC: hermain@benthamscience.net

To learn more about our Neuroscience Collection, please visit our website: http://bit.ly/2tOEZRo

Bentham Science Central Nervous System Collection

THE COLLECTION INCLUDE ARTICLES FROM THESE JOURNALS

 

CN_4-4.jpg  CNSAMC.JPG  cnsnddt-flyer.jpg  car

and many more Books…

✔ 130 Journals

✔ 7 Book Series

✔ 45 Books in Total 

 

FEATURES AND BENEFITS: 

♦ Access to over 11,000 scholarly articles covering several aspects of Central Nervous System

♦ Contents come from more than 100 Bentham Science Journals (40 journals indexed in JCR 2017 with impact factor rankings)

♦ Includes both; Original Research and Review Articles

♦ Research from leading institutions in USA, EUROPE, AUSTRALIA, JAPAN, CHINA and other regions

♦ Suitable for researchers in industry and academia wishing to keep updated with latest developments

♦ Easy access to institutions and individuals through IP-based authentication

♦ Access new Neuroscience Research included in this collection as soon as it is published

 

FLEXIBLE PACKAGES 

 Over 950 articles from 2018
 Over 2,764 articles from the last 3 years 
 More than 9,000 articles from the last 10 years

 

Annual addition of over 1,000 new Central Nervous System related articles each year

Tailor-made packages available for pharmaceuticals companies, research institutes, universities, hospitals, clinical/academic societies, and corporations.

 

You can also send your librarian’s contact information to us at marketing@benthamscience.net  CC: hermain@benthamscience.net

 

 

To learn more about our Central Nervous System Collection, please visit  our website: http://bit.ly/2tOEZRo

Press Release | Bentham Science journals improve impact factor ratings in 2019

 

The latest edition of Journal Citation Reports® 2019 has been published recently, and according to the report, Bentham Science Publishers (BSP) journals have significantly improved their Impact Factors. Current Neuropharmacology is leading the list again with the highest impact factor (IF: 4.568) among all the journals. In total, 40 BSP journals have received Impact Factor ratings this year. The latest results in the JCR 2019 reflect the high quality of research published by Bentham Science.

Journal Citation Reports (JCR) is an annual publication by Clarivate Analytics. JCR has been integrated with the Web of Science and is accessible from the Web of Science-Core Collections. Its purpose is to offer a systematic means to critically evaluate the world’s leading journals, with quantifiable, statistical information based on citation data.

Bentham Science publishes over 100 print & online scholarly subscription journals and books. Learn more about Bentham Science here: http://www.benthamscience.com

 

Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2019-06/bsp-bsl062019.php

EDITOR’S CHOICE ARTICLE | Models of Parkinson’s Disease with Special Emphasis on Drosophila melanogaster

Author(s): Ambreen Fatima, Smita Jyoti, Yasir Hasan Siddique*.

Graphical Abstract:

Abstract:

Background & Objective: Parkinson’s disease is the second most common neurodegenerative disorder affecting more than 1% of the population averaged 60 years of age. The majority of PD cases are sporadic and are probably caused by a combination of risk factors but 5-10% of the PD cases are familial. Due to the high degree of the gene, conservation in humans, mice and insects using an animal model system is a valuable approach to further elucidate the roles of the genes in PD.

 

Conclusion: The present review highlights the models used to study PD symptoms with special emphasis on Drosophila.

 

 

Browse the article details at: http://www.eurekaselect.com/164798/article

World Stroke Day, 2018!

 

world-stroke-day-bentham-science-avail-discount-banner-3

Around 80 million people living in the world today have experienced a stroke and over 50m survivors live with some form of permanent disability as a result. While for many, life after stroke won’t be quite the same, with the right care and support living a meaningful life is still possible. As millions of stroke survivors show us every day, it is possible to get #UpAgainAfterStroke.

 

Bentham Science publishes articles related to World Stroke Day in its Subscription based journals including:

 

TO AVAIL 20% DISCOUNT ON RELATED EBOOKS, KINDLY VISIT: HTTPS://EBOOKS.BENTHAMSCIENCE.COM/

 

AIMS & SCOPE – CNS & Neurological Disorders – Drug Targets

Aims & Scope

CNS & Neurological Disorders – Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes.

CNS & Neurological Disorders – Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies.

As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.

 

cnsnddt-flyer (1).jpg

 

For more details, please visit: https://benthamscience.com/journals/cns-and-neurological-disorders-drug-targets/aims-scope/#top 

MOST ACCESSED ARTICLE – The Efficacy and Safety of Pharmacological Treatments for Post-stroke Aphasia

Journal Name: CNS & Neurological Disorders – Drug Targets

Author(s): Xiaoyan Zhang, Bohui Shu, Dongdong Zhang, Lina Huang, Qizhi Fu, Ganqin Du*.

 

 

 

Graphical Abstract:

 

Abstract:

Background: Aphasia is a common complication after stroke, and traditional speech and language therapy (SLT) has a limited effect on post-stroke aphasia (PSA). While there has been an increasing number of controlled clinical trials on the efficacy of drugs in the treatment of PSA, there have been very few systematic reviews on the efficacy and safety of pharmacological treatments in people with PSA.

Objective: To evaluate the efficacy and safety of pharmacological interventions for PSA.

Methods: The Cochrane Central Register of Controlled Trials (CENTRA), PubMed, Embase, Chinese Journal Full-text Database (CJFD), China Biology Medicine disc (CBMdisc), Wanfang Data and VIP Information System were searched for randomized controlled trials about pharmacological treatments for PSA. Literature screening using the inclusion and exclusion criteria, data extraction and methodological quality assessment of the included studies were completed by two independent reviewers. Methodological quality was considered high for modified Jadad quality scale scores of 4 to 7. RevMan 5.3 software was used to conduct a meta-analysis of high-quality studies.

Results: Fifteen studies (578 participants) satisfied the eligibility criteria for this systematic review. Five trials (277 participants) assessed donepezil, four studies (124 participants) assessed memantine, three studies (72 participants) assessed bromocriptine, one trial (45 patients) evaluated galantamine, one study (21 patients) evaluated amphetamine, and one trial (39 patients) evaluated levodopa. The systematic review showed that donepezil achieved remarkable results in terms of the aphasia quotient (AQ) (SMD 0.82, 95% CI 0.48-1.17, P < 0.00001), repetition ability (SMD 0. 81, 95% CI 0.57-1.06, P < 0.00001), naming ability (SMD 0.56, 95% CI 0.29-0. 84, P < 0.00001), auditory comprehension (SMD 0.85, 95% CI 0.58-1. 13, P< 0.00001) and oral expression (SMD 0.90, 95% CI 0.54-1.26, P < 0.00001). Memantine showed no pronounced improvement in auditory comprehension (SMD 0.35, 95% CI -0.05-0.74, P = 0.09) but did improve the AQ (SMD 0.57, 95% CI 0.09-1.06, P = 0. 02), naming ability (SMD 0.81, 95% CI 0.38-1.25, P = 0.0002), spontaneous speech (SMD 0.76, 95% CI 0. 39- 1.13, P < 0.0001), and repetition ability (SMD 0.37, 95% CI 0.01-0.73, P = 0.04). Bromocriptine showed pronounced improvement in naming ability (SMD -0.20, 95% CI- 0.67-0.26, P = 0.39), verbal fluency (SMD 0.02, 95% CI 0.53-0.56, P = 0.95), and repetition ability (SMD 0.29, 95% CI -0.23-0. 81, P = 0.28). There is limited and inconclusive evidence for galantamine, amphetamine and levodopa.

Conclusion: Current evidence suggests that drugs, such as donepezil and memantine, can improve the prognosis of PSA. Donepezil has a significant effect in improving the ability of auditory comprehension, naming, repetition and oral expression. Memantine has a significant effect in improving the ability of naming, spontaneous speech and repetition. Bromocriptine showed no significant improvements in the treatment of aphasia after stroke. Data regarding galantamine, amphetamine and levodopa in the treatment of aphasia after stroke are limited and inconclusive.

 

 

For more details, please visit: http://www.eurekaselect.com/163587

OPEN ACCESS ARTICLE – Physiological and Morphological Principles Underpinning Recruitment of the Cerebellar Reserve

Journal Name: CNS & Neurological Disorders – Drug Targets

Author(s): Shinji Kakei*, Takahiro Ishikawa, Jongho Lee, Takeru Honda, Donna S. Hoffman.

 

 

Graphical Abstract:

 

Abstract:

Background: In order to optimize outcomes of novel therapies for cerebellar ataxias (CAs), it is desirable to start these therapies while declined functions are restorable: i.e. while the so-called cerebellar reserve remains.

Objective: In this mini-review, we tried to define and discuss the cerebellar reserve from physiological and morphological points of view.

Method: The cerebellar neuron circuitry is designed to generate spatiotemporally organized outputs, regardless of the region. Therefore, the cerebellar reserve may be defined as a mechanism to restore its proper input-output organization of the cerebellar neuron circuitry, when it is damaged. Then, the following four components are essential for recruitment of the cerebellar reserve: operational local neuron circuitry; proper combination of mossy fiber inputs to be integrated; climbing fiber inputs to instruct favorable reorganization of the integration; deep cerebellar nuclei to generate reorganized outputs.

Results: We discussed three topics related to these resources, 1) principles of generating organized cerebellar outputs, 2) redundant mossy fiber inputs to the cerebellum, 3) plasticity of the cerebellar neuron circuitry.

Conclusion: To make most of the cerebellar reserve, it is desirable to start any intervention as early as possible when the cerebellar cell loss is minimal or even negligible. Therefore, an ideal future therapy for degenerative cerebellar diseases should start before consuming the cerebellar reserve at all. In the meantime, our real challenge is to establish a reliable method to identify the decrease in the cerebellar reserve as early as possible.

 

For more details, please visit: http://www.eurekaselect.com/160508

EDITOR’S CHOICE – N-3 (Omega-3) Fatty Acids: Effects on Brain Dopamine Systems and Potential Role in the Etiology and Treatment of Neuropsychiatric Disorders

Journal: CNS & Neurological Disorders – Drug Targets

Author(s): Michelle Healy-Stoffel, Beth Levant

Graphical Abstract:

 

Abstract:

Background & Objective: A number of neuropsychiatric disorders, including Parkinson’s disease, schizophrenia, attention deficit hyperactivity disorder, and, to some extent, depression, involve dysregulation of the brain dopamine systems. The etiology of these diseases is multifactorial, involving genetic and environmental factors. Evidence suggests that inadequate levels of n-3 (omega- 3) polyunsaturated fatty acids (PUFA) in the brain may represent a risk factor for these disorders. These fatty acids, which are derived from the diet, are a major component of neuronal membranes and are of particular importance in brain development and function. Low levels of n-3 PUFAs in the brain affect the brain dopamine systems and, when combined with appropriate genetic and other factors, increase the risk of developing these disorders and/or the severity of the disease. This article reviews the neurobiology of n-3 PUFAs and their effects on dopaminergic function.

Conclusion: Clinical studies supporting their role in the etiologies of diseases involving the brain dopamine systems and the potential of n-3 PUFAs in the treatment of these disorders are discussed.

Read more here: http://www.eurekaselect.com/161234/article

New Issue:: CNS & Neurological Disorders – Drug Targets 16, Issue 10

CNS & Neurological Disorders – Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in neurological and central nervous system (CNS) disorders e.g. disease specific proteins, receptors, enzymes, genes.

CNS & Neurological Disorders – Drug Targets publishes guest edited thematic issues written by leaders in the field covering a range of current topics of CNS & neurological drug targets. The journal also accepts for publication original research articles, letters, reviews and drug clinical trial studies.

As the discovery, identification, characterization and validation of novel human drug targets for neurological and CNS drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.

cnsnddt-flyer

Articles from the journal CNS & Neurological Disorders – Drug Targets 16, Issue 10:

For details on the articles, please visit this link:: https://bit.ly/2vcL7n4

%d bloggers like this: